← Eichor
Study identifier: NCT06274047 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

PROSTATE-IQ: Parallel RandOmized STudy of Personalized Apalutamide Treatment and Evaluation to Improve Quality of Life in Post-Operative Radiation With Androgen Axis Suppression. A Phase III Multi-center Study for Men With Detectable PSA After Prostatectomy for Prostate Cancer.

Condition: Androgen Axis Suppression · Prostatectomy · Prostate Cancer  ·  Sponsor: M.D. Anderson Cancer Center

PhasePhase 3
Planned participants120
Who can joinMale, 18 Years to no upper limit
Healthy volunteersNo

About this study

1. Personalize treatment for prostate cancer based on how aggressive the disease is and 2. Learn if apalutamide-based treatment can help to reduce fatigue and other side effects of treatment in participants who are being treated with radiation therapy for prostate cancer, as compared to standard therapy.

This description comes directly from the study's public registry record.

Talk to the study team

Karen Hoffman, MD  ·  (713) 563-2339  ·  khoffman1@mdanderson.org

Always discuss trial participation with your own doctor first.

Locations (6)

Banner MD AndersonGilbert, Arizona, United StatesRecruiting
Rush MD AndersonChicago, Illinois, United StatesRecruiting
University of Kansas Medical CenterKansas City, Kansas, United StatesRecruiting
Dana-Farber Cancer InstituteBoston, Massachusetts, United StatesRecruiting
Memorial Sloan Kettering Cancer CenterNew York, New York, United StatesRecruiting
MD Anderson Cancer CenterHouston, Texas, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06274047